BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. [PMID: 20091503 DOI: 10.1002/14651858.cd000171.pub3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 180] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Reference Citation Analysis]
2 Maokola WM, Ngowi BJ, Mahande MJ, Todd J, Robert M, Msuya SE. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania. PLoS One 2021;16:e0254082. [PMID: 34255776 DOI: 10.1371/journal.pone.0254082] [Reference Citation Analysis]
3 Knight GM, Dodd PJ, Grant AD, Fielding KL, Churchyard GJ, White RG. Tuberculosis prevention in South Africa. PLoS One 2015;10:e0122514. [PMID: 25849558 DOI: 10.1371/journal.pone.0122514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
4 van de Water BJ, Meyer TN, Wilson M, Young C, Gaunt B, le Roux KW. TB prevention cascade at a district hospital in rural Eastern Cape, South Africa. Public Health Action 2021;11:97-100. [PMID: 34159070 DOI: 10.5588/pha.20.0055] [Reference Citation Analysis]
5 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
6 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis 2012;55:1532-49. [PMID: 22942202 DOI: 10.1093/cid/cis732] [Cited by in Crossref: 123] [Cited by in F6Publishing: 100] [Article Influence: 13.7] [Reference Citation Analysis]
8 Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, Lawn SD. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS One 2012;7:e49928. [PMID: 23209621 DOI: 10.1371/journal.pone.0049928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
9 Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J 2014;17:26. [PMID: 24932337 DOI: 10.11604/pamj.2014.17.26.2641] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015;386:2344-53. [PMID: 26515679 DOI: 10.1016/S0140-6736(15)00323-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 46] [Article Influence: 16.5] [Reference Citation Analysis]
11 Evenblij K, Verbon A, van Leth F. Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design. BMC Public Health 2016;16:915. [PMID: 27585867 DOI: 10.1186/s12889-016-3539-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Korean Society for AIDS. The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections. Infect Chemother 2016;48:54-60. [PMID: 27104018 DOI: 10.3947/ic.2016.48.1.54] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
14 Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV-no more excuses. Lancet Glob Health 2017;5:e1048-9. [PMID: 29025618 DOI: 10.1016/S2214-109X(17)30390-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Al-Darraji HA, Kamarulzaman A, Altice FL. Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health 2014;14:22. [PMID: 24405607 DOI: 10.1186/1471-2458-14-22] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
16 Green EP, Catalani C, Diero L, Carter EJ, Gardner A, Ndwiga C, Keny A, Owiti P, Israelski D, Biondich P. Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial. Trials 2015;16:141. [PMID: 25885266 DOI: 10.1186/s13063-015-0558-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Pullar ND, Steinum H, Bruun JN, Dyrhol-Riise AM. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study. BMC Infect Dis 2014;14:667. [PMID: 25515915 DOI: 10.1186/s12879-014-0667-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
18 Yuen CM, Millones AK, Contreras CC, Lecca L, Becerra MC, Keshavjee S. Tuberculosis household accompaniment to improve the contact management cascade: A prospective cohort study. PLoS One 2019;14:e0217104. [PMID: 31100097 DOI: 10.1371/journal.pone.0217104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis 2018;22:125-32. [PMID: 29506608 DOI: 10.5588/ijtld.17.0486] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
20 Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. Asia Pac Allergy 2014;4:54-67. [PMID: 24527412 DOI: 10.5415/apallergy.2014.4.1.54] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
21 Olsen AI, Andersen HE, Aßmus J, Djupvik JA, Gran G, Skaug K, Mørkve O. Management of latent tuberculous infection in Norway in 2009: a descriptive cross-sectional study. Public Health Action 2013;3:166-71. [PMID: 26393022 DOI: 10.5588/pha.13.0011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 LaCourse SM, Deya RW, Graham SM, Masese LN, Jaoko W, Mandaliya KN, Overbaugh J, McClelland RS. Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 2017;76:74-81. [PMID: 28797022 DOI: 10.1097/QAI.0000000000001461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
24 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
25 Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 2016;5:e10. [PMID: 26839146 DOI: 10.1038/emi.2016.10] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 14.4] [Reference Citation Analysis]
26 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
27 Cheallaigh CN, Fitzgerald I, Grace J, Singh GJ, El-Eraki N, Gibbons N, Keane J, Rogers TR, Clarke S, Bergin C. Interferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden country. PLoS One 2013;8:e53330. [PMID: 23382842 DOI: 10.1371/journal.pone.0053330] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
28 Yuen CM, Weyenga HO, Kim AA, Malika T, Muttai H, Katana A, Nganga L, Cain KP, De Cock KM. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012. PLoS One 2014;9:e99880. [PMID: 24937804 DOI: 10.1371/journal.pone.0099880] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
29 Karo B, Krause G, Castell S, Kollan C, Hamouda O, Haas W; ClinSurv HIV Study Group. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis 2017;17:517. [PMID: 28743248 DOI: 10.1186/s12879-017-2627-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;:CD007545. [PMID: 23828580 DOI: 10.1002/14651858.CD007545.pub2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
31 Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, Pacheco AG, Chaisson RE, Durovni B. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr 2014;66:552-8. [PMID: 24853308 DOI: 10.1097/QAI.0000000000000219] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
32 Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7:e36001. [PMID: 22558301 DOI: 10.1371/journal.pone.0036001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
33 Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Ngabirano C, Adong J, Linas BP, Jacobson KR, Hahn JA. Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. PLoS One 2020;15:e0235261. [PMID: 32614873 DOI: 10.1371/journal.pone.0235261] [Reference Citation Analysis]
34 Al-Mozaini M, Alrahbeni T, Dirar Q, Alotibi J, Alrajhi A. HIV in the Kingdom of Saudi Arabia: Can We Change the Way We Deal with Co-Infections. Infect Drug Resist 2021;14:111-7. [PMID: 33500633 DOI: 10.2147/IDR.S270355] [Reference Citation Analysis]
35 Adeniyi OV, Selanto-Chairman N, Owolabi EO, Ajayi AI, Kayembe DK, Ter Goon D, Gordana A, Lambert J. Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa. BMC Public Health 2019;19:1407. [PMID: 31664978 DOI: 10.1186/s12889-019-7769-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kibret KT, Yalew AW, Belaineh BG, Asres MM. Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PLoS One 2013;8:e64488. [PMID: 23762214 DOI: 10.1371/journal.pone.0064488] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
37 Chehab JC, Vilakazi-Nhlapo AK, Vranken P, Peters A, Klausner JD. Current integration of tuberculosis (TB) and HIV services in South Africa, 2011. PLoS One 2013;8:e57791. [PMID: 23469242 DOI: 10.1371/journal.pone.0057791] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
38 Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016;30:1607-15. [PMID: 27243774 DOI: 10.1097/QAD.0000000000001098] [Cited by in Crossref: 80] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
39 Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013;13:852-8. [PMID: 23954450 DOI: 10.1016/S1473-3099(13)70187-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
40 Daher A, Pitta L, Santos T, Barreira D, Pinto D. Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry method in a randomised, crossover study. Mem Inst Oswaldo Cruz 2015;110:543-50. [PMID: 26038960 DOI: 10.1590/0074-02760140458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Dodd PJ, Millington KA, Ghani AC, Mutsvangwa J, Butterworth AE, Lalvani A, Corbett EL. Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. Am J Epidemiol 2010;171:1037-45. [PMID: 20382638 DOI: 10.1093/aje/kwq017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Gupta A, Chandrasekhar A, Gupte N, Patil S, Bhosale R, Sambarey P, Ghorpade S, Nayak U, Garda L, Sastry J, Bharadwaj R, Bollinger RC; Byramjee Jeejeebhoy Medical College–Johns Hopkins University Study Group. Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis. Clin Infect Dis 2011;53:1015-8. [PMID: 21940417 DOI: 10.1093/cid/cir605] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
43 Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011;9:415-30. [PMID: 21504399 DOI: 10.1586/eri.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
44 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
45 Kagujje M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health 2019;19:1329. [PMID: 31640657 DOI: 10.1186/s12889-019-7652-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tiruneh F, Deyas Y. How Far Does Highly Active Antiretroviral Treatment Reduce TB Incidence among Children? A Marginal Structural Modeling Analysis, Southwest Ethiopia. Ethiop J Health Sci 2020;30:653-60. [PMID: 33911825 DOI: 10.4314/ejhs.v30i5.3] [Reference Citation Analysis]
47 Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis 2015;15:368. [PMID: 26306511 DOI: 10.1186/s12879-015-1085-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
48 Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014;14:91. [PMID: 24555539 DOI: 10.1186/1471-2334-14-91] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 8.9] [Reference Citation Analysis]
49 Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014;28:1463-72. [PMID: 24681417 DOI: 10.1097/QAD.0000000000000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
50 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Shayo GA, Chitama D, Moshiro C, Aboud S, Bakari M, Mugusi F. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. BMC Public Health 2017;18:35. [PMID: 28724374 DOI: 10.1186/s12889-017-4597-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
52 Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016;387:1198-209. [PMID: 27025337 DOI: 10.1016/S0140-6736(16)00546-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 8.6] [Reference Citation Analysis]
53 Magombedze G, Dowdy D, Mulder N. Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy. Front Bioeng Biotechnol 2013;1:4. [PMID: 25023946 DOI: 10.3389/fbioe.2013.00004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
54 Bell LC, Pollara G, Pascoe M, Tomlinson GS, Lehloenya RJ, Roe J, Meldau R, Miller RF, Ramsay A, Chain BM, Dheda K, Noursadeghi M. In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. PLoS Pathog 2016;12:e1005469. [PMID: 26986567 DOI: 10.1371/journal.ppat.1005469] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
55 Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 221] [Cited by in F6Publishing: 199] [Article Influence: 24.6] [Reference Citation Analysis]
56 Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One 2013;8:e64915. [PMID: 23741419 DOI: 10.1371/journal.pone.0064915] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
57 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
58 Balcha TT, Skogmar S, Sturegård E, Schön T, Winqvist N, Reepalu A, Jemal ZH, Tibesso G, Björk J, Björkman P. A Clinical Scoring Algorithm for Determination of the Risk of Tuberculosis in HIV-Infected Adults: A Cohort Study Performed at Ethiopian Health Centers. Open Forum Infect Dis 2014;1:ofu095. [PMID: 25734163 DOI: 10.1093/ofid/ofu095] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
59 Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 Suppl 5:S5-13. [PMID: 21079429 DOI: 10.1097/01.aids.0000391010.02774.6f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
60 Kerkhoff AD, Gupta A, Samandari T, Lawn SD. The proportions of people living with HIV in low and middle-income countries who test tuberculin skin test positive using either a 5 mm or a 10 mm cut-off: a systematic review. BMC Infect Dis 2013;13:307. [PMID: 23834892 DOI: 10.1186/1471-2334-13-307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 Kim HY, Hanrahan CF, Dowdy DW, Martinson N, Golub J, Bridges JFP. The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis. AIDS Care 2018;30:1298-305. [PMID: 29595060 DOI: 10.1080/09540121.2018.1455958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011;50:202-12. [PMID: 21717066 DOI: 10.1007/s12026-011-8229-7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 9.4] [Reference Citation Analysis]
63 Dirix V, Schepers K, Massinga-Loembe M, Worodria W, Colebunders R, Singh M, Locht C, Kestens L, Mascart F; TB-IRIS study group. Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda. J Acquir Immune Defic Syndr 2016;72:344-52. [PMID: 27306506 DOI: 10.1097/QAI.0000000000000980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
64 Pontororing GJ, Kenangalem E, Lolong DB, Waramori G, Sandjaja, Tjitra E, Price RN, Kelly PM, Anstey NM, Ralph AP. The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infect Dis 2010;10:362. [PMID: 21605474 DOI: 10.1186/1471-2334-10-362] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
65 Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 2018;78:54-61. [PMID: 29406428 DOI: 10.1097/QAI.0000000000001641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Viana PVS, Paiva NS, Villela DAM, Bastos LS, de Souza Bierrenbach AL, Basta PC. Factors associated with death in patients with tuberculosis in Brazil: Competing risks analysis. PLoS One 2020;15:e0240090. [PMID: 33031403 DOI: 10.1371/journal.pone.0240090] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24 Suppl 5:S49-S56. [PMID: 21079428 DOI: 10.1097/01.aids.0000391022.95412.a6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
68 Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, Win T, Cristofani S, Telnov A, Fernandez M, Ciglenecki I. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Health Action 2018;8:20-4. [PMID: 29581939 DOI: 10.5588/pha.17.0087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
69 Komba FF, Frumence G. Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania. Pan Afr Med J 2021;38:197. [PMID: 33995803 DOI: 10.11604/pamj.2021.38.197.26752] [Reference Citation Analysis]
70 Lee CY, Wu PH, Lu PL, Tsai HC. Changing Spectrum of Opportunistic Illnesses among HIV-Infected Taiwanese Patients in Response to a 10-Year National Anti-TB Programme. J Clin Med 2019;8:E163. [PMID: 30717133 DOI: 10.3390/jcm8020163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Tiruneh F, Deyas Y. Effect of highly active antiretroviral treatment on TB incidence among HIV infected children and their clinical profile, retrospective cohort study, South West Ethiopia. Sci Rep 2020;10:21468. [PMID: 33293656 DOI: 10.1038/s41598-020-78466-0] [Reference Citation Analysis]
72 Garg RK, Sinha MK. Tuberculous meningitis in patients infected with human immunodeficiency virus. J Neurol 2011;258:3-13. [PMID: 20848123 DOI: 10.1007/s00415-010-5744-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
73 Gounder CR, Wada NI, Kensler C, Violari A, McIntyre J, Chaisson RE, Martinson NA. Active tuberculosis case-finding among pregnant women presenting to antenatal clinics in Soweto, South Africa. J Acquir Immune Defic Syndr 2011;57:e77-84. [PMID: 21436710 DOI: 10.1097/QAI.0b013e31821ac9c1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
74 Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulm Med 2013;2013:601737. [PMID: 23476763 DOI: 10.1155/2013/601737] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
75 Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis 2014;14:281. [PMID: 24886159 DOI: 10.1186/1471-2334-14-281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
76 Peters JA, Heunis C, Kigozi G, Osoba T, van der Walt M. Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public Health Action 2015;5:30-5. [PMID: 26400599 DOI: 10.5588/pha.14.0033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS One 2014;9:e87166. [PMID: 24498298 DOI: 10.1371/journal.pone.0087166] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
78 Ayele HT, van Mourik MS, Bonten MJ. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infect Dis 2015;15:334. [PMID: 26269094 DOI: 10.1186/s12879-015-1089-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
79 Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Sci Rep 2020;10:21823. [PMID: 33311520 DOI: 10.1038/s41598-020-78737-w] [Reference Citation Analysis]
80 Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
81 Suryavanshi N, Murrill M, Gupta A, Hughes M, Hesseling A, Kim S, Naini L, Jones L, Smith B, Gupte N, Dawson R, Mave V, Meshram S, Mendoza-Ticona A, Sanchez J, Kumarasamy N, Comins K, Conradie F, Shenje J, Nerette Fontain S, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo U, Cristina Garcia Ferreira A, Okeyo E, Swindells S, Churchyard G, Shah NS. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis 2020;70:436-45. [PMID: 30919881 DOI: 10.1093/cid/ciz254] [Reference Citation Analysis]
82 Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger D, Bernadi S, Butler K, Chiappini E, Clayden P, Della Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier HJ, Tudor-Williams G, Welch SB; (PENTA Steering Committee). Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med 2018;19:e1-e42. [PMID: 25649230 DOI: 10.1111/hiv.12217] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
83 Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care 2017;29:936-42. [PMID: 28147705 DOI: 10.1080/09540121.2017.1283390] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
84 Catalani C, Green E, Owiti P, Keny A, Diero L, Yeung A, Israelski D, Biondich P. A clinical decision support system for integrating tuberculosis and HIV care in Kenya: a human-centered design approach. PLoS One 2014;9:e103205. [PMID: 25170939 DOI: 10.1371/journal.pone.0103205] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
85 Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20. [PMID: 21732833 DOI: 10.1056/NEJMoa1005136] [Cited by in Crossref: 202] [Cited by in F6Publishing: 97] [Article Influence: 20.2] [Reference Citation Analysis]
86 Bonnett SA, Dennison D, Files M, Bajpai A, Parish T. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis. PLoS One 2018;13:e0198059. [PMID: 30332412 DOI: 10.1371/journal.pone.0198059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
87 Carmone A, Rodriguez CA, Frank TD, Kiromat M, Bongi PW, Kuno RG, Palou T, Franke MF. Increasing isoniazid preventive therapy uptake in an HIV program in rural Papua New Guinea. Public Health Action 2017;7:193-8. [PMID: 29201654 DOI: 10.5588/pha.17.0011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev 2017;8:CD006418. [PMID: 28850172 DOI: 10.1002/14651858.CD006418.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
89 Minja LT, Hella J, Mbwambo J, Nyandindi C, Omary US, Levira F, Mpagama S, Shimwela M, Okuma J, Gagneux S, Bruce RD, Reither K. High burden of tuberculosis infection and disease among people receiving medication-assisted treatment for substance use disorder in Tanzania. PLoS One 2021;16:e0250038. [PMID: 33914753 DOI: 10.1371/journal.pone.0250038] [Reference Citation Analysis]
90 Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, Granich R. Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis 2014;18:1159-65. [PMID: 25216828 DOI: 10.5588/ijtld.13.0571] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
91 Jarrett BA, Woznica DM, Tilchin C, Mpungose N, Motlhaoleng K, Golub JE, Martinson NA, Hanrahan CF. Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics. AIDS Behav 2020;24:1106-17. [PMID: 31549265 DOI: 10.1007/s10461-019-02675-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Sculier D, Getahun H, Lienhardt C. Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research. J Int AIDS Soc 2011;14 Suppl 1:S5. [PMID: 21967874 DOI: 10.1186/1758-2652-14-S1-S5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
93 Sulis G, Centis R, Sotgiu G, D'Ambrosio L, Pontali E, Spanevello A, Matteelli A, Zumla A, Migliori GB. Recent developments in the diagnosis and management of tuberculosis. NPJ Prim Care Respir Med 2016;26:16078. [PMID: 27808163 DOI: 10.1038/npjpcrm.2016.78] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
94 Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, Fielding KL. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med 2016;14:45. [PMID: 27004413 DOI: 10.1186/s12916-016-0589-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
95 Long R, Niruban S, Heffernan C, Cooper R, Fisher D, Ahmed R, Egedahl ML, Fur R. A 10-year population based study of 'opt-out' HIV testing of tuberculosis patients in Alberta, Canada: national implications. PLoS One 2014;9:e98993. [PMID: 24911262 DOI: 10.1371/journal.pone.0098993] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Saito S, Howard AA, Reid MJ, Elul B, Scardigli A, Verkuijl S, Nyaruhirira AU, Nash D. TB diagnostic capacity in sub-Saharan African HIV care settings. J Acquir Immune Defic Syndr 2012;61:216-20. [PMID: 22732465 DOI: 10.1097/QAI.0b013e3182638ec7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
97 Kim HY, Dowdy DW, Martinson NA, E Golub J, Bridges JFP, Hanrahan CF. Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey. J Int AIDS Soc 2018;21:e25143. [PMID: 29972628 DOI: 10.1002/jia2.25143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
98 Batista Jd, de Albuquerque Mde F, Maruza M, Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One 2013;8:e63916. [PMID: 23675515 DOI: 10.1371/journal.pone.0063916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
99 Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat 2020;2020:7025738. [PMID: 32411454 DOI: 10.1155/2020/7025738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS One 2012;7:e42479. [PMID: 22848764 DOI: 10.1371/journal.pone.0042479] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
101 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
102 Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, Joloba M, Katamba A, Cose S, Dockrell HM, Elliott AM. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis 2015;15:438. [PMID: 26493989 DOI: 10.1186/s12879-015-1201-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
103 Kerrigan D, Tudor C, Motlhaoleng K, Lebina L, Qomfu C, Variava E, Chon S, Martinson N, Golub JE. Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial. BMC Health Serv Res 2018;18:288. [PMID: 29661197 DOI: 10.1186/s12913-018-3088-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
104 Sinha P, Shenoi SV, Friedland GH. Opportunities for community health workers to contribute to global efforts to end tuberculosis. Glob Public Health 2020;15:474-84. [PMID: 31516079 DOI: 10.1080/17441692.2019.1663361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
105 Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016;30:2715-23. [PMID: 27782966 DOI: 10.1097/QAD.0000000000001235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
106 Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
107 Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M. Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis (Edinb) 2018;109:61-8. [PMID: 29559122 DOI: 10.1016/j.tube.2017.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
108 Machekera SM, Wilkinson E, Hinderaker SG, Mabhala M, Zishiri C, Ncube RT, Timire C, Takarinda KC, Sengai T, Sandy C. A comparison of the yield and relative cost of active tuberculosis case-finding algorithms in Zimbabwe. Public Health Action 2019;9:63-8. [PMID: 31417855 DOI: 10.5588/pha.18.0098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
109 Seddon JA, Paton J, Nademi Z, Keane D, Williams B, Williams A, Welch SB, Liebeschutz S, Riddell A, Bernatoniene J, Patel S, Martinez-Alier N, McMaster P, Kampmann B. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax 2016;71:932-9. [PMID: 27335104 DOI: 10.1136/thoraxjnl-2015-207687] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
110 Naranbhai V, Kim S, Fletcher H, Cotton MF, Violari A, Mitchell C, Nachman S, McSherry G, McShane H, Hill AV, Madhi SA. The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life. BMC Med 2014;12:120. [PMID: 25034889 DOI: 10.1186/s12916-014-0120-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
111 M'imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev 2012;:CD006591. [PMID: 22592714 DOI: 10.1002/14651858.CD006591.pub2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
112 Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 2018;77:405-12. [PMID: 29239900 DOI: 10.1097/QAI.0000000000001610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
114 Hutchinson E, Droti B, Gibb D, Chishinga N, Hoskins S, Phiri S, Parkhurst J. Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ 2011;89:312-6. [PMID: 21479096 DOI: 10.2471/BLT.10.077743] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
115 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Escudero JN, Hawn TR, John-Stewart GC. Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children. BMJ Open 2020;10:e034308. [PMID: 31969368 DOI: 10.1136/bmjopen-2019-034308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist 2012;5:163-73. [PMID: 23226700 DOI: 10.2147/IDR.S29180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc 2011;8:288-93. [PMID: 21653530 DOI: 10.1513/pats.201010-064WR] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
118 Lima VD, Granich R, Phillips P, Williams B, Montaner JS. Potential impact of the US President's Emergency Plan for AIDS relief on the tuberculosis/HIV coepidemic in selected Sub-Saharan African countries. J Infect Dis 2013;208:2075-84. [PMID: 23911712 DOI: 10.1093/infdis/jit406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
119 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015;29:351-9. [PMID: 25686683 DOI: 10.1097/QAD.0000000000000535] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
120 Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013;5:180ra49. [PMID: 23576815 DOI: 10.1126/scitranslmed.3005260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
121 Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, Maokamnerd Y, Pevzner E, Whitehead S, Kanphukiew A, Monkongdee P, Martin M. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS One 2017;12:e0184986. [PMID: 28949995 DOI: 10.1371/journal.pone.0184986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
122 Coelho L, Cardoso SW, Amancio RT, Moreira RI, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One 2014;9:e98666. [PMID: 24901419 DOI: 10.1371/journal.pone.0098666] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
123 Adams LV, Maseko TSB, Talbot EA, Grande SW, Mkhontfo MM, Simelane ZZ, Achilla AA, Haumba SM. Integrated and patient-selected care facilitates completion of isoniazid preventive therapy in Eswatini. Public Health Action 2019;9:153-8. [PMID: 32042607 DOI: 10.5588/pha.19.0038] [Reference Citation Analysis]
124 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
125 Lodi S, Emenyonu NI, Marson K, Kwarisiima D, Fatch R, McDonell MG, Cheng DM, Thirumurthy H, Gandhi M, Camlin CS, Muyindike WR, Hahn JA, Chamie G. The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial. Trials 2021;22:355. [PMID: 34016158 DOI: 10.1186/s13063-021-05304-7] [Reference Citation Analysis]
126 Klautau GB, da Mota NVF, Salles MJC, Burattini MN, Rodrigues DS. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study. BMC Infect Dis 2018;18:585. [PMID: 30453903 DOI: 10.1186/s12879-018-3508-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
127 Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 2016;11:e0165614. [PMID: 27906986 DOI: 10.1371/journal.pone.0165614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
128 Clark IT, Lobato MN, Gutierrez J, Sosa LE. HIV status among patients with tuberculosis and HIV testing practices by Connecticut health care providers. J Int Assoc Provid AIDS Care 2013;12:261-5. [PMID: 23442493 DOI: 10.1177/2325957412473649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 110] [Cited by in F6Publishing: 43] [Article Influence: 55.0] [Reference Citation Analysis]
130 Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health 2015;15:346. [PMID: 25886730 DOI: 10.1186/s12889-015-1719-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
131 Dierberg KL, Chaisson RE. Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment. Clin Chest Med 2013;34:217-28. [PMID: 23702172 DOI: 10.1016/j.ccm.2013.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
132 Coelho LE, Cardoso SW, Amancio RT, Moreira RI, Ribeiro SR, Coelho AB, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infect Dis 2016;16:134. [PMID: 27001753 DOI: 10.1186/s12879-016-1462-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
133 Godoy P. Guidelines on controlling latent tuberculosis infection to support tuberculosis elimination. Rev Esp Sanid Penit 2021;23:28-36. [PMID: 33847703 DOI: 10.18176/resp.00028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis 2018;22:1435-42. [PMID: 30606315 DOI: 10.5588/ijtld.18.0370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P. Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. Am J Respir Crit Care Med 2019;199:564-71. [PMID: 30335466 DOI: 10.1164/rccm.201806-1053PP] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
136 Kall MM, Coyne KM, Garrett NJ, Boyd AE, Ashcroft AT, Reeves I, Anderson J, Bothamley GH. Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. BMC Infect Dis 2012;12:107. [PMID: 22558946 DOI: 10.1186/1471-2334-12-107] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
137 Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, Ofotokun I, Tenna A. Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis 2013;17:1396-401. [PMID: 24125440 DOI: 10.5588/ijtld.13.0315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
138 Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S136-44. [PMID: 22797735 DOI: 10.1097/QAI.0b013e31825cfe8e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
139 Rangaka MX, Gideon HP, Wilkinson KA, Pai M, Mwansa-Kambafwile J, Maartens G, Glynn JR, Boulle A, Fielding K, Goliath R, Titus R, Mathee S, Wilkinson RJ. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur Respir J 2012;39:163-71. [PMID: 21719487 DOI: 10.1183/09031936.00058911] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
140 Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391. [PMID: 21267059 DOI: 10.1371/journal.pmed.1000391] [Cited by in Crossref: 223] [Cited by in F6Publishing: 230] [Article Influence: 22.3] [Reference Citation Analysis]
141 Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med 2019;16:e1002882. [PMID: 31415563 DOI: 10.1371/journal.pmed.1002882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
142 Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG; TB MAC TB-HIV meeting participants. How can mathematical models advance tuberculosis control in high HIV prevalence settings? Int J Tuberc Lung Dis 2014;18:509-14. [PMID: 24903784 DOI: 10.5588/ijtld.13.0773] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
143 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
144 van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. AIDS 2016;30:2845-53. [PMID: 27755106 DOI: 10.1097/QAD.0000000000001252] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
145 MacPherson P, Lebina L, Motsomi K, Bosch Z, Milovanovic M, Ratsela A, Lala S, Variava E, Golub JE, Webb EL, Martinson NA. Prevalence and risk factors for latent tuberculosis infection among household contacts of index cases in two South African provinces: Analysis of baseline data from a cluster-randomised trial. PLoS One 2020;15:e0230376. [PMID: 32182274 DOI: 10.1371/journal.pone.0230376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philos Trans R Soc Lond B Biol Sci 2015;370:20140306. [PMID: 25918446 DOI: 10.1098/rstb.2014.0306] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
147 Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. [PMID: 22905358 DOI: 10.7448/ias.15.2.17396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
148 Takarinda KC, Harries AD, Sandy C, Mutasa-Apollo T, Zishiri C. Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in Zimbabwe. Public Health Action 2016;6:164-8. [PMID: 27695678 DOI: 10.5588/pha.16.0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
149 Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang WH. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open 2019;9:e029058. [PMID: 31147370 DOI: 10.1136/bmjopen-2019-029058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
150 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Mecha J, Escudero JN, Hawn TR, John-Stewart G. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. Clin Infect Dis 2021;73:e337-44. [PMID: 32564076 DOI: 10.1093/cid/ciaa827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, Xing Z, Hernández-Pando R. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol. 2013;171:283-297. [PMID: 23379435 DOI: 10.1111/cei.12015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
152 Howard AA, Hirsch-Moverman Y, Saito S, Gadisa T, Daftary A, Melaku Z. The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods cluster randomized trial. Contemp Clin Trials Commun 2017;6:46-54. [PMID: 28626811 DOI: 10.1016/j.conctc.2017.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
153 Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011;56:230-8. [PMID: 21239993 DOI: 10.1097/QAI.0b013e31820b07ab] [Cited by in Crossref: 177] [Cited by in F6Publishing: 75] [Article Influence: 17.7] [Reference Citation Analysis]
154 Liu Y, Ndumnego OC, Chen T, Kim RS, Jenny-Avital ER, Ndung'u T, Wilson D, Achkar JM. Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis. Pathogens 2018;7:E26. [PMID: 29495442 DOI: 10.3390/pathogens7010026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
155 Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365:21-31. [PMID: 21732834 DOI: 10.1056/nejmoa1011214] [Cited by in Crossref: 89] [Cited by in F6Publishing: 53] [Article Influence: 8.9] [Reference Citation Analysis]
156 Dye C, Williams BG. Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region. Bull World Health Organ 2019;97:405-14. [PMID: 31210678 DOI: 10.2471/BLT.18.228577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
157 Naidoo K, Naidoo K, Padayatchi N, Abdool Karim Q. HIV-Associated Tuberculosis. Clin Dev Immunol 2011;2011:585919. [PMID: 20871843 DOI: 10.1155/2011/585919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
158 Holmberg V, Soini H, Kivelä P, Ollgren J, Ristola M. Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998-2015. BMC Infect Dis 2019;19:264. [PMID: 30885144 DOI: 10.1186/s12879-019-3890-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
159 Charan J, Goyal JP, Reljic T, Emmanuel P, Patel A, Kumar A. Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. Pediatr Infect Dis J 2018;37:773-80. [PMID: 29280783 DOI: 10.1097/INF.0000000000001879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
160 Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis 2020;24:396-402. [PMID: 32317063 DOI: 10.5588/ijtld.18.0740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
161 Rhines AS, Feldman MW, Bendavid E. Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. AIDS 2018;32:2129-40. [PMID: 30096067 DOI: 10.1097/QAD.0000000000001959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014;14:281-90. [PMID: 24602844 DOI: 10.1016/S1473-3099(13)70692-3] [Cited by in Crossref: 309] [Cited by in F6Publishing: 207] [Article Influence: 44.1] [Reference Citation Analysis]
163 Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A 2014;111:5325-30. [PMID: 24706842 DOI: 10.1073/pnas.1317660111] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
164 Gengiah TN, Gray AL, Naidoo K, Karim QA. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 2011;10:559-74. [PMID: 21204737 DOI: 10.1517/14740338.2011.546783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
165 Amoakwa K, Martinson NA, Moulton LH, Barnes GL, Msandiwa R, Chaisson RE. Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virus. Open Forum Infect Dis 2015;2:ofu120. [PMID: 26034751 DOI: 10.1093/ofid/ofu120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
166 Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 2011;6:e22927. [PMID: 21829557 DOI: 10.1371/journal.pone.0022927] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
167 Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV; AIDS Clinical Trials Group A5279 Study Team. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis 2015;61:1322-7. [PMID: 26082504 DOI: 10.1093/cid/civ464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
168 Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni B, Chaisson RE. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015;60:639-45. [PMID: 25365974 DOI: 10.1093/cid/ciu849] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
169 Nathavitharana RR, Bond P, Dramowski A, Kotze K, Lederer P, Oxley I, Peters JA, Rossouw C, van der Westhuizen HM, Willems B, Ting TX, von Delft A, von Delft D, Duarte R, Nardell E, Zumla A. Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis. Presse Med 2017;46:e53-62. [PMID: 28256382 DOI: 10.1016/j.lpm.2017.01.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
170 Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-81. [PMID: 21756508 DOI: 10.5588/ijtld.10.0483] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
171 Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis 2018;22:723-30. [PMID: 29914597 DOI: 10.5588/ijtld.17.0835] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
172 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
173 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
174 Moore DA. What can we offer to 3 million MDRTB household contacts in 2016? BMC Med 2016;14:64. [PMID: 27039310 DOI: 10.1186/s12916-016-0610-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
175 Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690. [PMID: 24835842 DOI: 10.1016/s0140-6736(14)60162-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 98] [Article Influence: 21.4] [Reference Citation Analysis]
176 Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, Silva-Caso W, Bernabe-Ortiz A. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One 2011;6:e27610. [PMID: 22110689 DOI: 10.1371/journal.pone.0027610] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
177 Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A. Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. J Acquir Immune Defic Syndr 2014;65:551-6. [PMID: 24346636 DOI: 10.1097/QAI.0000000000000085] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
178 Mills HL, Cohen T, Colijn C. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. J R Soc Interface 2011;8:1510-20. [PMID: 21508012 DOI: 10.1098/rsif.2011.0160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
179 Al-Darraji HA, Wong KC, Yeow DG, Fu JJ, Loeliger K, Paiji C, Kamarulzaman A, Altice FL. Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care. J Subst Abuse Treat 2014;46:144-9. [PMID: 24074846 DOI: 10.1016/j.jsat.2013.08.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
180 . International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. J Int AIDS Soc 2016;19:21487. [PMID: 27780519 DOI: 10.7448/IAS.19.8.21487] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]